AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Abstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif. –(BUSINESS WIRE)–Aug. 31, 2026– AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and